Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 142

1.

Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.

Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GO, Skotheim RI, Lothe RA, Tarpey PS, Campbell P, Flanagan A, Myklebost O, Meza-Zepeda LA.

Oncotarget. 2016 Feb 2;7(5):5273-88. doi: 10.18632/oncotarget.6567.

2.

Genomic landscape of liposarcoma.

Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Myklebost O, Yang H, Dugas M, Meza-Zepeda LA, Silberman AW, Forscher C, Tyner JW, Ogawa S, Koeffler HP.

Oncotarget. 2015 Dec 15;6(40):42429-44. doi: 10.18632/oncotarget.6464.

3.

Genome sequencing in research requires a new approach to consent.

Budin-Ljøsne I, Bentzen HB, Solbakk JH, Myklebost O.

Tidsskr Nor Laegeforen. 2015 Dec 1;135(22):2031-2. doi: 10.4045/tidsskr.15.0944. eCollection 2015 Dec 1. English, Norwegian. No abstract available.

4.

HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.

Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stenman G, Stock RS, Ståhlberg A, Åman P.

Oncotarget. 2016 Jan 5;7(1):433-45. doi: 10.18632/oncotarget.6336.

5.

Norwegian Cancer Genomics Consortium: a platform for research on personalized cancer medicine in a public health system.

Myklebost O.

Drug Discov Today. 2015 Dec;20(12):1419-21. doi: 10.1016/j.drudis.2015.10.003. Epub 2015 Oct 28. No abstract available.

PMID:
26520668
6.

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A.

Blood Cancer J. 2015 Mar 20;5:e299. doi: 10.1038/bcj.2015.24.

7.

Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA.

Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E.

Oncotarget. 2015 Feb 10;6(4):2451-65.

8.

Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death.

Naderi EH, Skah S, Ugland H, Myklebost O, Sandnes DL, Torgersen ML, Josefsen D, Ruud E, Naderi S, Blomhoff HK.

Mol Cancer. 2015 Jan 27;14:14. doi: 10.1186/s12943-014-0278-9.

9.

The architecture and evolution of cancer neochromosomes.

Garsed DW, Marshall OJ, Corbin VD, Hsu A, Di Stefano L, Schröder J, Li J, Feng ZP, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O, Meza-Zepeda L, Holloway AJ, Pedeutour F, Choo KH, Damore MA, Deans AJ, Papenfuss AT, Thomas DM.

Cancer Cell. 2014 Nov 10;26(5):653-67. doi: 10.1016/j.ccell.2014.09.010. Epub 2014 Nov 10.

10.

Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines.

Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O, Munthe E.

PLoS One. 2014 Aug 22;9(8):e103873. doi: 10.1371/journal.pone.0103873. eCollection 2014.

11.

Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

Tubio JM, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O'Meara S, Anderson E, Maddison M, Gamble S; ICGC Breast Cancer Group; ICGC Bone Cancer Group; ICGC Prostate Cancer Group, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, van't Veer L, Caldas C, Desmedt C, Sotiriou C, Aparicio S, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL, Van de Vijver M, Vincent-Salomon A, Van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ.

Science. 2014 Aug 1;345(6196):1251343. doi: 10.1126/science.1251343.

12.

Performance comparison of four exome capture systems for deep sequencing.

Chilamakuri CS, Lorenz S, Madoui MA, Vodák D, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA.

BMC Genomics. 2014 Jun 9;15:449. doi: 10.1186/1471-2164-15-449.

13.

The regulatory landscape of osteogenic differentiation.

Håkelien AM, Bryne JC, Harstad KG, Lorenz S, Paulsen J, Sun J, Mikkelsen TS, Myklebost O, Meza-Zepeda LA.

Stem Cells. 2014 Oct;32(10):2780-93. doi: 10.1002/stem.1759.

14.

Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model.

Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA.

Mol Cancer. 2014 Apr 28;13:93. doi: 10.1186/1476-4598-13-93.

15.

Generation and characterization of an immortalized human mesenchymal stromal cell line.

Skårn M, Noordhuis P, Wang MY, Veuger M, Kresse SH, Egeland EV, Micci F, Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S, Haraldsen G, Kvalheim G, Meza-Zepeda LA, Myklebost O.

Stem Cells Dev. 2014 Oct 1;23(19):2377-89. doi: 10.1089/scd.2013.0599. Epub 2014 Jun 30.

16.

The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines.

Stratford EW, Daffinrud J, Munthe E, Castro R, Waaler J, Krauss S, Myklebost O.

Cancer Med. 2014 Feb;3(1):36-46. doi: 10.1002/cam4.170. Epub 2013 Dec 17.

17.

Epigenetic regulation and functional characterization of microRNA-142 in mesenchymal cells.

Skårn M, Barøy T, Stratford EW, Myklebost O.

PLoS One. 2013 Nov 13;8(11):e79231. doi: 10.1371/journal.pone.0079231. eCollection 2013.

18.

Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.

Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goody V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM.

Nat Genet. 2013 Dec;45(12):1479-82. doi: 10.1038/ng.2814. Epub 2013 Oct 27. Erratum in: Nat Genet. 2014 Mar;46(3):316. Goodie, Victoria [corrected to Goody, Victoria].

19.

Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing.

Nome T, Thomassen GO, Bruun J, Ahlquist T, Bakken AC, Hoff AM, Rognum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA, Skotheim RI.

Transl Oncol. 2013 Oct 1;6(5):546-53. eCollection 2013.

20.

Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes.

Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA, Myklebost O.

Br J Cancer. 2013 Oct 15;109(8):2228-36. doi: 10.1038/bjc.2013.549. Epub 2013 Sep 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk